Correction: A conjugate based on anti-HER2 diaffibody and auristatin E targets HER2-positive cancer cells (Int. j. mol. sci., (2017) 18, 10.3390/ijms18020401);A conjugate based on anti-HER2 diaffibody and auristatin e targets HER2-positive cancer cells

International Journal of Molecular Sciences

Volumn 18, Issue 2, 2017, Pages

  Serwotka Suszczak, Anna M ^a   Sochaj Gregorczyk, Alicja M ^a   Pieczykolan, Jerzy ^b   Krowarsch, Daniel ^a   Jelen, Filip ^c   Otlewski, Jacek ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b Celon Pharma Ltd   (Poland)

^c Pure Biologics Ltd   (Poland)

Author keywords

Diaffibody; HER2; Monomethyl auristatin E (MMAE); Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; VEDOTIN; AMINOBENZOIC ACID DERIVATIVE; ANTIBODY CONJUGATE; AURISTATIN; MONOCLONAL ANTIBODY; OLIGOPEPTIDE; PROTEIN BINDING;

ARTICLE; CANCER CELL; CELL VIABILITY; CHROMATOGRAPHY; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC50; MASS SPECTROMETRY; MTT ASSAY; NUCLEAR MAGNETIC RESONANCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SURFACE PLASMON RESONANCE; THERMOSTABILITY; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ISOLATION AND PURIFICATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROTEIN STABILITY; THERMODYNAMICS; TUMOR CELL LINE;

AMINOBENZOATES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOCONJUGATES; MOLECULAR TARGETED THERAPY; NEOPLASMS; OLIGOPEPTIDES; PROTEIN BINDING; PROTEIN STABILITY; RECEPTOR, ERBB-2; THERMODYNAMICS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85013004924     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms19113676     Document Type: Erratum

References (56)

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics. CA Cancer J. Clin. 2015, 65, 5–29.
2. Kreitman, R.J. Immunotoxins for targeted cancer therapy. AAPS J. 2006, 18, E532–E551.
3. Teicher, B.A.; Chari, R.V.J. Antibody conjugate therapeutics: Challenges and potential. Clin. Cancer Res. 2011, 15, 6389–6397.
4. Thomas, A.; Teicher, B.A.; Hassan, R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016, 17, e254–e262.
5. Sochaj, A.M.; Świderska, K.W.; Otlewski, J. Current methods for the synthesis of homogeneous antibody-drug conjugates. Biotechnol. Adv. 2015, 1, 775–784.
6. Teicher, B.A.; Doroshow, J.H. The promise of antibody-drug conjugates. N. Engl. J. Med. 2012, 8, 1847–1848.
7. Kovtun, Y.V.; Goldmacher, V.S. Cell killing by antibody-drug conjugates. Cancer Lett. 2007, 255, 232–240.
8. Senter, P.D.; Sievers, E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 2012, 30, 631–637.
9. Deng, C.; Pan, B.; O’Connor, O.A. Brentuximab vedotin. Clin. Cancer Res. 2013, 19, 22–27.
10. Niculescu-Duvaz, I. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. Curr. Opin. Mol. Ther. 2010, 12, 350–360. [PubMed]
11. Peddi, P.F.; Hurvitz, S.A. Trastuzumab emtansine: The first targeted chemotherapy for treatment of breast cancer. Future Oncol. 2013, 9, 319–326.
12. Saber, H.; Leighton, J.K. An FDA oncology analysis of antibody-drug conjugates. Regul. Toxicol. Pharmacol. 2015, 71, 444–452.
13. Adams, G.P.; Weiner, L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 2005, 23, 1147–1157.
14. Chames, P.; van Regenmortel, M.; Weiss, E.; Baty, D. Therapeutic antibodies: Successes, limitations and hopes for the future. Br. J. Pharmacol. 2009, 2, 220–233.
15. Casi, G.; Neri, D. Antibody-drug conjugates and small molecule-drug conjugates: Opportunities and challenges for the development of selective anticancer cytotoxic agents. J. Med. Chem. 2015, 25, 8751–8761.
16. Junutula, J.R.; Bhakta, S.; Raab, H.; Ervin, K.E.; Eigenbrot, C.; Vandlen, R.; Scheller, R.H.; Lowman, H.B. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J. Immunol. Methods 2008, 20, 41–52.
17. Nelson, A.L.; Reichert, J.M. Development trends for therapeutic antibody fragments. Nat. Biotechnol. 2009, 27, 331–337.
18. Holliger, P.; Prospero, T.; Winter, G. “Diabodies”: Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 1993, 15, 6444–6448.
19. Bird, R.E.; Hardman, K.D.; Jacobson, J.W.; Johnson, S.; Kaufman, B.M.; Lee, S.M.; Lee, T.; Pope, S.H.; Riordan, G.S.; Whitlow, M. Single-chain antigen-binding proteins. Science 1988, 21, 423–426.
20. Cortez-Retamozo, V.; Backmann, N.; Senter, P.D.; Wernery, U.; de Baetselier, P.; Muyldermans, S.; Revets, H. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 2004, 15, 2853–2857.
21. Oliveira, S.; Heukers, R.; Sornkom, J.; Kok, R.J.; van Bergen En Henegouwen, P.M. Targeting tumors with nanobodies for cancer imaging and therapy. J. Control. Release 2013, 28, 607–617.
22. Skerra, A. Alternative non-antibody scaffolds for molecular recognition. Curr. Opin. Biotechnol. 2007, 18, 295–304.
23. Koide, A.; Abbatiello, S.; Rothgery, L.; Koide, S. Probing protein conformational changes in living cells by using designer binding proteins: Application to the estrogen receptor. Proc. Natl. Acad. Sci. USA 2002, 5, 1253–1258.
24. Skerra, A. Lipocalins as a scaffold. Biochim. Biophys. Acta 2000, 18, 337–350.
25. Stumpp, M.T.; Binz, H.K.; Amstutz, P. DARPins: A new generation of protein therapeutics. Drug Discov. Today 2008, 13, 695–701.
26. Nord, K.; Gunneriusson, E.; Ringdahl, J.; Ståhl, S.; Uhlén, M.; Nygren, P.A. Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain. Nat. Biotechnol. 1997, 15, 772–777.
27. Wurch, T.; Pierré, A.; Depil, S. Novel protein scaffolds as emerging therapeutic proteins: From discovery to clinical proof-of-concept. Trends Biotechnol. 2012, 30, 575–582.
28. Wikman, M.; Steffen, A.C.; Gunneriusson, E.; Tolmachev, V.; Adams, G.P.; Carlsson, J.; Ståhl, S. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng. Des. Sel. 2004, 17, 455–462.
29. Löfblom, J.; Feldwisch, J.; Tolmachev, V.; Carlsson, J.; Ståhl, S.; Frejd, F.Y. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010, 18, 2670–2680.
30. Neve, R.M.; Lane, H.A.; Hynes, N.E. The role of overexpressed HER2 in transformation. Ann. Oncol. 2001, 12 (Suppl. 1), S9–S13.
31. Tai, W.; Mahato, R.; Cheng, K. The role of HER2 in cancer therapy and targeted drug delivery. J. Control. Release 2010, 15, 264–275.
32. Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 9, 177–182.
33. HER2:342. Nucl. Med. Biol. 2015, 42, 541–546.
34. Sörensen, J.; Velikyan, I.; Sandberg, D.; Wennborg, A.; Feldwisch, J.; Tolmachev, V.; Orlova, A.; Sandström, M.; Lubberink, M.; Olofsson, H.; et al. measuring her2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET/CT. Theranostics 2016, 1, 262–271.
35. Lee, S.B.; Hassan, M.; Fisher, R.; Chertov, O.; Chernomordik, V.; Kramer-Marek, G.; Gandjbakhche, A.; Capala, J. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin. Cancer Res. 2008, 15, 3840–3849.
36. Steffen, A.C.; Wikman, M.; Tolmachev, V.; Adams, G.P.; Nilsson, F.Y.; Ståhl, S.; Carlsson, J. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother. Radiopharm. 2005, 20, 239–248.
37. Steffen, A.C.; Orlova, A.; Wikman, M.; Nilsson, F.Y.; Ståhl, S.; Adams, G.P.; Tolmachev, V.; Carlsson, J. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 631–638.
38. Sreerama, N.; Woody, R.W. A self-consistent method for the analysis of protein secondary structure from circular dichroism. Anal. Biochem. 1993, 15, 32–44.
39. Sreerama, N.; Woody, R.W. Computation and analysis of protein circular dichroism spectra. Methods Enzymol. 2004, 383, 318–351. [PubMed]
40. Zheng, D.; Aramini, J.M.; Montelione, G.T. Validation of helical tilt angles in the solution NMR structure of the Z domain of Staphylococcal protein A by combined analysis of residual dipolar coupling and NOE data. Protein Sci. 2004, 13, 549–554.
41. Sochaj-Gregorczyk, A.M.; Serwotka-Suszczak, A.M.; Otlewski, J. A novel Affibody-auristatin E conjugate with a potent and selective activity against HER2+ cell lines. J. Immunother. 2016, 39, 223–232.
42. Holliday, D.L.; Speirs, V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011, 13, 215.
43. Löfblom, J.; Frejd, F.Y.; Ståhl, S. Non-immunoglobulin based protein scaffolds. Curr. Opin. Biotechnol. 2011, 22, 843–848.
44. Koduvayur, S.P.; Su, Y.; Kay, B.K.; Lavie, A. Targeted delivery of deoxycytidine kinase to HER2-positive cells enhances the efficacy of the nucleoside analog fludarabine. PLoS ONE 2016, 11, e157114.
45. Liu, H.; Seijsing, J.; Frejd, F.Y.; Tolmachev, V.; Gräslund, T. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain. Int. J. Oncol. 2015, 47, 601–609.
46. Zielinski, R.; Lyakhov, I.; Hassan, M.; Kuban, M.; Shafer-Weaver, K.; Gandjbakhche, A.; Capala, J. HER2-affitoxin: A potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin. Cancer Res. 2011, 1, 5071–5081.
47. Sörensen, J.; Sandberg, D.; Sandström, M.; Wennborg, A.; Feldwisch, J.; Tolmachev, V.; Åström, G.; Lubberink, M.; Garske-Román, U.; Carlsson, J.; et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J. Nucl. Med. 2014, 5, 730–735.
48. Honarvar, H.; Westerlund, K.; Altai, M.; Sandström, M.; Orlova, A.; Tolmachev, V.; Karlström, A.E. Feasibility of Affibody molecule-based PNA-mediated radionuclide pretargeting of malignant tumors. Theranostics 2016, 1, 93–103.
49. Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341–354.
50. Witton, C.J.; Reeves, J.R.; Going, J.J.; Cooke, T.G.; Bartlett, J.M. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 2003, 200, 290–297.
51. 3 Binding Proteins for Use in Anti-Cancer Therapies. Ph.D. Thesis, University of Wrocław, Wrocław, Poland, 13 April 2016.
52. Ekerljung, L.; Lindborg, M.; Gedda, L.; Frejd, F.Y.; Carlsson, J.; Lennartsson, J. Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line. Biochem. Biophys. Res. Commun. 2008, 377, 489–494.
53. Doronina, S.O.; Toki, B.E.; Torgov, M.Y.; Mendelsohn, B.A.; Cerveny, C.G.; Chace, D.F.; DeBlanc, R.L.; Gearing, R.P.; Bovee, T.D.; Siegall, C.B.; et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 2003, 7, 778–784.
54. Francisco, J.A.; Cerveny, C.G.; Meyer, D.L.; Mixan, B.J.; Klussman, K.; Chace, D.F.; Rejniak, S.X.; Gordon, K.A.; DeBlanc, R.; Toki, B.E.; et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 4, 1458–1465.
55. Whitmore, L.; Wallace, B.A. Protein secondary structure analyses from circular dichroism spectroscopy: Methods and reference databases. Biopolymers 2008, 89, 392–400.
56. Zakrzewska, M.; Krowarsch, D.; Wiedlocha, A.; Olsnes, S.; Otlewski, J. Highly stable mutants of human fibroblast growth factor-1 exhibit prolonged biological action. J. Mol. Biol. 2005, 352, 860–875.